According to the anti-PD-1 and anti-PD-L1 immunotherapy cohorts, low-risk group of patients in HCC, SKM, LGG and bladder cancers showed significant clinical benefits for anti-PD-1 or anti-PD-L1 treatment 115,116,146,170. Here, CD274 is linked to hepatocellular carcinoma.